Gene · 3205
Papers4,255
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 4,255
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. | Nature | 2023 | 36922593 | PubTator, text mining | PubMed |
| Emerging role of miRNAs, lncRNAs, and circRNAs in pregnancy-associated diseases. | Chin Med J (Engl) | 2023 | 36914956 | PubTator, text mining | PubMed |
| Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs. | J Pharm Anal | 2023 | 36908859 | PubTator, text mining | PubMed |
| Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study. | Protein Cell | 2023 | 36905391 | PubTator, text mining | PubMed |
| CRISPR-assisted transcription activation by phase-separation proteins. | Protein Cell | 2023 | 36905356 | PubTator, text mining | PubMed |
| Endometrial Injury Upregulates Expression of Receptivity Genes in Women with Implantation Failure. | Int J Environ Res Public Health | 2023 | 36900953 | PubTator, text mining | PubMed |
| LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. | Cells | 2023 | 36899941 | PubTator, text mining | PubMed |
| Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells. | Cancer Cell | 2023 | 36898380 | PubTator, text mining | PubMed |
| The oncogenetic landscape and clinical impact of BCL11B alterations in adult and pediatric T-cell acute lymphoblastic leukemia. | Haematologica | 2023 | 36891734 | PubTator, text mining | PubMed |
| Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. | Life Sci Alliance | 2023 | 36878637 | PubTator, text mining | PubMed |
| Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets. | MedComm (2020) | 2023 | 36875159 | PubTator, text mining | PubMed |
| Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. | J Thorac Oncol | 2023 | 36870519 | PubTator, text mining | PubMed |
| The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer. | Medicine (Baltimore) | 2023 | 36862865 | PubTator, text mining | PubMed |
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. | Am J Hematol | 2023 | 36861732 | PubTator, text mining | PubMed |
| 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. | Cell Prolif | 2023 | 36855955 | PubTator, text mining | PubMed |
| The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications. | Exp Mol Med | 2023 | 36854773 | PubTator, text mining | PubMed |
| Regulatory de novo mutations underlying intellectual disability. | Life Sci Alliance | 2023 | 36854624 | PubTator, text mining | PubMed |
| Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. | Cell Rep | 2023 | 36848231 | PubTator, text mining | PubMed |
| Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. | Signal Transduct Target Ther | 2023 | 36843114 | PubTator, text mining | PubMed |
| A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. | Cancer Cell Int | 2023 | 36841758 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3205/papers?page=25